Research reports coverage on drug delivery stocks—Valeant Pharma, Delcath Systems, Alkermes, and Adamis Pharma.
Stock-Callers.com this week took a closer look at Valeant Pharmaceuticals International Inc., Delcath Systems Inc., Alkermes PLC, and Adamis Pharmaceuticals Corp. The firms are generally structured as corporations and offer higher-than-average dividend yields, according to the service.
Laval, Canada-headquartered Valeant Pharmaceuticals International Inc.’s stock rose 0.31 percent, finishing last Friday’s trading session at $12.83. A total volume of 8.88 million shares was traded. The company’s shares have surged 36.78 percent in the last month. The stock is trading above its 50-day moving average by 18.49 percent. Additionally, shares of Valeant Pharma, which operates as a pharmaceutical and medical device company worldwide, have a Relative Strength Index (RSI) of 57.83.
On May 22, 2017, Valeant Pharmaceuticals International’s wholly owned subsidiary, Bausch + Lomb, announced the launch of renu Advanced Formula multi-purpose solution for soft and silicone hydrogel contact lenses. The formula combines three disinfectants and two moisture agents to provide excellent lens cleaning and disinfection, in addition to all-day comfort.
Shares in New York-headquartered Delcath Systems Inc. ended at $0.02, up 2.49 percent from the last trading session. The stock recorded a trading volume of 48.38 million shares, which was above its three months average volume of 15.28 million shares. The company’s shares are trading 60.62 percent below their 50-day moving average. Moreover, shares of Delcath Systems, which focuses on the treatment of primary and metastatic liver cancers, have an RSI of 22.65.
On May 9, 2017, Delcath Systems announced financial results for the three months ended March 31, 2017. Revenue for the quarter was $0.74 million; selling, general and administrative expenses were approximately $2.4 million; R&D expenses were $2.3 million; total operating expenses were $4.7 million; and net loss was $11.3 million. The company also had cash and cash equivalents of $6.4 million as of March 31, 2017.
On Friday, shares in Dublin, Ireland-headquartered Alkermes PLC recorded a trading volume of 571,086 shares. The stock declined 0.41 percent, closing the day at $57.70. The company’s shares have gained 2.49 percent in the last one month, 4.15 percent over the previous three months, and 3.81 percent on an YTD basis. The stock is trading 6.69% above its 200-day moving average. Additionally, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide, have an RSI of 46.95.
At the close of trading on Friday, shares in San Diego, California-headquartered Adamis Pharmaceuticals Corp. recorded a trading volume of 413,665 shares. The stock finished the session 2.63 percent lower at $3.70. The company’s shares have gained 12.12 percent in the previous three months and 17.46 percent since the start of this year. The stock is trading above its 200-day moving average by 10.83 percent. Furthermore, shares of Adamis Pharma, which develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the U.S., have an RSI of 43.52.
About Stock Callers
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps.
SC said it has not been compensated—directly or indirectly—for producing or publishing this document.
(Source: PR Newswire)